Articles

Two Victorian men and one woman have been charged following a joint investigation into an alleged criminal syndicate importing Performance and Image Enhancing Drugs (PIEDs) into Australia.

The TGA, assisted by the New South Wales Police Force, has conducted targeted enforcement action across 2 sites in south-west Sydney.

Patient information materials are required to be supplied with implantable and active implantable medical devices in Australia. Abby’s story highlights the practical importance of the patient information materials.

We are providing an updated statement on the IChEMS and the prohibitions relevant to chemicals such as certain PFAS chemicals, UV-328 and Dechlorane Plus

The TGA has begun consultation on a proposal to remove Andrographis paniculata (Andrographis) from the list of permitted ingredients in listed medicines.

We’ve updated the Listed Medicine Compliance Reports database with the results of compliance reviews covering 32 listed medicines.

We have opened an 8-week public consultation seeking improvements to the regulation of sunscreens in Australia.

We have issued 6 infringement notices totalling $23,760 to 3 health practitioners for the alleged unlawful importation of unapproved therapeutic goods.

Information for health professionals about medicines with safety related updates to their Product Information.

Taking too much vitamin B6 can result in harmful side effects, including nerve damage known as ‘peripheral neuropathy’, which can be severe and irreversible. If you’re not sure if you’re taking too much vitamin B6 have a chat with your doctor or pharmacist.

Information on the recently announced concept papers proposing to update the Good Manufacturing Practice (GMP) guide for Annex 6 and Annex 15.

Listed medicine ingredients and requirements for their use have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 1) 2026, which commenced on 1 March 2026.

We have published a new FAQ and Guidance page on the use of legislative powers related to recalls and other market actions.

Oral preparations containing more than 50 mg but not more than 200 mg per recommended daily dose of vitamin B6 will be rescheduled as Pharmacist Only Medicines from 1 June 2027.

Information for health professionals about medicines with safety related updates to their Product Information.

In September 2025, the Therapeutic Goods Administration (TGA) issued a public safety alert after TGA laboratory testing revealed significant dose inconsistencies in unapproved melatonin products bought from overseas websites. Some products contained up to 400% more melatonin, while others contained less than stated or none.

On 3 February 2026 the TGA, with support from the NSW Police Force and the Australian Federal Police (AFP), conducted targeted enforcement action in Burwood, New South Wales, seizing more than 57,000 illegal vaping goods.

TGA has issued infringement notices to Prime Medic Group Pty Ltd (Prime Medic) and an individual for the alleged unlawful advertising of weight loss medicines in contravention of the Therapeutic Goods Act 1989 (the Act).

The Adverse Event Management System (AEMS) has moved to the cloud, delivering improved system stability and security.

We have issued 11 infringement notices totalling $43,560, to 6 individuals, for the alleged importation and unlawful advertising of therapeutic goods.

The TGA is updating information for nitrosamine impurities and other nitroso-structure impurities in medicines including acceptable intakes (AI).

We conducted targeted compliance reviews of selected listed medicines using indications related to diarrhoea that are required to display a warning statement

On 23 January 2026 we, with support from Victoria Police, executed a search warrant at a pop up retail store in Inverloch, Victoria.

This statement provides guidance to industry about how the Therapeutic Goods Act 1989 applies in relation to sunscreen labelling.

The TGA Compliance Principles 2026 and 2027 outlines our strategic approach to monitoring and enforcing regulatory compliance for the import, export, manufacture, supply and advertising of therapeutic goods in Australia.